5 - / 3 - 三甲基) - 2 - 印林衍生物具有抗干白素-1活性
Özge Soylu-Eter1,2, Zekiye Şeyma Sevinçli3, Betül Ersoy4,5
1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey.
Archiv der Pharmazie
|October 10, 2023
概括
研究人员开发了一种新型的2-英多林衍生物来抑制互白素-1 (IL-1) 活性. 化合物78和81显示出强大的,非有毒的IL-1受体 (IL-1R) 抑制,显示出治疗炎症疾病的希望.
科学领域:
- 药用化学 医学化学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 促炎性细胞因子介素-1 (IL-1) 参与了许多炎症性疾病的发病.
- 已经出现了2-英多林衍生物作为细胞因子反应的潜在调节剂.
研究的目的:
- 选和开发具有强有力的抗干白素-1 (抗IL-1) 活性的新型2-英多林衍生物.
- 确定化合物向IL-1受体 (IL-1R) 用于治疗炎症疾病.
主要方法:
- 使用in silico对接研究来评估2-indolinone衍生物的结合相互作用和疗效.
- 对IL-1R抑制作用的新型5-/三甲) -1-H-醇-2,3-3-4-烯西西米卡巴) 的合成和体外评价.
- 化合物的类似药物特性和结合相互作用的in silico和in vitro评估.
主要成果:
- 最初的查发现了具有显著IL-1R抑制作用的5-/(三甲) -1-H-二醇-2,3-二3-(4-二甲) .
- 选择了52 (IC50 = 0.09μM) 和65 (IC50 = 0.07μM) 的化合物作为化合物.
- 新型衍生物,特别是化合物78 (IC50 = 0.01 μM) 和81 (IC50 = 0.02 μM),表现出强大的,无毒的IL-1R抑制和有利的类似药物的特性,优于化合物.
结论:
- 新的2-英多林衍生物,特别是化合物78和81,显示出作为向IL-1R的治疗剂的显著潜力.
- 这些化合物表现出强大的抗炎活性和有利的药理动力学特征.
- 对这些化合物的进一步研究可能会导致对IL-1介导的炎症性疾病的新疗法.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
150
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
150
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
173
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
173
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
136
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
136
01:19Antiasthma Drugs: Leukotriene Modifiers
324
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
324
01:29Drugs for Treatment of Ulcerative Colitis in IBD
152
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
152